Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Early EIT-Guided PEEP Titration on Pulmonary Physiology in Patients With Moderate-to-Severe ARDS Undergoing Prone Positioning (EIT-PEEP-PRONE) (EIT-PEEP-PRONE)

26. august 2026 opdateret af: XIE MIN

A Randomized Controlled Trial of Early EIT-Guided PEEP Titration on Pulmonary Physiology in Moderate-to-Severe ARDS Patients Undergoing Prone Positioning

Background: Electrical impedance tomography (EIT)-guided PEEP titration has been shown to improve regional ventilation distribution, increase respiratory system compliance, and reduce mechanical power in patients with acute respiratory distress syndrome (ARDS), but its effect on mortality remains unproven. In patients with moderate-to-severe ARDS, prone positioning for 4 hours allows pulmonary ventilation and perfusion to reach a new steady state, with optimization of ventilation-perfusion (V/Q) matching and other pulmonary physiological parameters. However, whether dynamic PEEP titration guided by EIT at this time point can further optimize V/Q matching and other pulmonary physiological parameters compared with conventional methods has not been reported.

Objective: To investigate whether EIT-guided PEEP titration performed at 4 hours after prone positioning initiation can further optimize V/Q matching and other pulmonary physiological parameters in patients with moderate-to-severe ARDS undergoing prone positioning.

Methods: This is a prospective, single-center, randomized, open-label, parallel-controlled physiological study. A total of 40 patients with moderate-to-severe ARDS (Berlin definition, PaO₂/FiO₂ < 150 mmHg) will be enrolled and randomized in a 1:1 ratio to either the EIT-guided group or the control group. PEEP intervention will be performed at 4 hours after prone positioning initiation (T1) in both groups: the EIT group receives EIT-guided PEEP titration, while the control group receives PEEP set according to the ARDSNet/PEEP-FiO₂ table. The primary outcome is V/Q matching percentage assessed by EIT at 18 hours of prone positioning (T2) and 6 hours after supine repositioning (T3). Secondary outcomes include respiratory mechanics, EIT-derived parameters (regional ventilation distribution, global inhomogeneity index, center of ventilation), oxygenation indices, echocardiographic measures of cardiac function, and clinical outcomes (28-day mortality, ventilator-free days, ICU length of stay, etc.).

Conclusion: This study will provide physiological evidence for early EIT-guided PEEP titration in patients with moderate-to-severe ARDS undergoing prone positioning, and will lay the foundation for future large-scale clinical trials.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

40

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Min Xie, MD, PhD
  • Telefonnummer: +86-27-83665204
  • E-mail: Xie_m@126.com

Undersøgelse Kontakt Backup

Studiesteder

    • Hubei
      • Wuhan, Hubei, Kina, 430030
        • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  1. Diagnosis of moderate-to-severe ARDS according to the Berlin definition, with a PaO₂/FiO₂ ratio < 150 mmHg on optimal mechanical ventilation.
  2. Clinical decision has been made to place a central venous catheter (internal jugular or subclavian vein) for clinical management.

Exclusion Criteria:

  1. Pregnancy or postpartum state.
  2. BMI > 35 kg/m².
  3. Duration of invasive mechanical ventilation > 48 hours at enrollment.
  4. Severe hemodynamic instability (mean arterial pressure < 65 mmHg on norepinephrine ≥ 0.5 μg/kg/min).
  5. Immediate need for veno-venous extracorporeal membrane oxygenation (VV-ECMO) at enrollment.
  6. Contraindications to prone positioning or EIT monitoring, including but not limited to: facial or cervical trauma; unstable spinal, femoral, pelvic, or rib fractures; recent cardiac surgery; pneumothorax; elevated intracranial pressure; pacemaker or implantable cardioverter-defibrillator; severe chronic lung disease (e.g., severe COPD, asthma, interstitial lung disease); severe cardiac dysfunction (New York Heart Association Class III or IV, acute coronary syndrome, sustained ventricular tachyarrhythmia, or cardiogenic shock).
  7. Lack of informed consent from legally authorized representative.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Støttende pleje
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: EIT-Guided PEEP Titration Group
PEEP will be titrated using EIT monitoring at 4 hours after prone positioning initiation (T1). The optimal PEEP will be determined at the intersection of the cumulative collapse and overdistension curves, or at the lowest global inhomogeneity index if the intersection occurs between two PEEP levels.
PEEP titration is performed during mechanical ventilation to optimize respiratory mechanics and ventilation-perfusion matching in patients with ARDS.
Aktiv komparator: ARDSNet/PEEP-FiO₂ Table Group
PEEP will be set according to the ARDSNet/PEEP-FiO₂ table at 4 hours after prone positioning initiation (T1).
PEEP will be set according to the ARDSNet/PEEP-FiO₂ table at 4 hours after prone positioning initiation (T1).

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Ventilation-Perfusion (V/Q) Matching Percentage
Tidsramme: At 18 hours of prone positioning (T2) and at 6 hours after supine repositioning (T3)
V/Q matching percentage assessed by electrical impedance tomography (EIT) using the EIT Evaluation Tool (SDMI) V2.7.1. V/Q matching reflects the efficiency of pulmonary gas exchange and is calculated from regional ventilation and perfusion distribution maps.
At 18 hours of prone positioning (T2) and at 6 hours after supine repositioning (T3)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Respiratory System Compliance
Tidsramme: Baseline, T2 (18h prone), and T3 (6h post-supine)
Respiratory system compliance (Crs) calculated as tidal volume divided by driving pressure (plateau pressure minus PEEP), measured under volume-controlled ventilation.
Baseline, T2 (18h prone), and T3 (6h post-supine)
Driving Pressure
Tidsramme: At baseline (T0), at 18 hours of prone positioning (T2), and at 6 hours after supine repositioning (T3)
Driving pressure (DP) calculated as plateau pressure (Pplat) minus PEEP, measured under volume-controlled ventilation.
At baseline (T0), at 18 hours of prone positioning (T2), and at 6 hours after supine repositioning (T3)
EIT-Derived Regional Ventilation Distribution
Tidsramme: At baseline (T0), at 18 hours of prone positioning (T2), and at 6 hours after supine repositioning (T3)
Regional ventilation distribution assessed by EIT, expressed as percentage of tidal impedance variation in four regions of interest (ROIs): ventral (ROI 1), mid-ventral (ROI 2), mid-dorsal (ROI 3), and dorsal (ROI 4), each corresponding to 25% of the anteroposterior diameter, Center of Ventilation (CoV), Global Inhomogeneity Index (GI), Shunt, Dead Space.
At baseline (T0), at 18 hours of prone positioning (T2), and at 6 hours after supine repositioning (T3)
RVEDA/LVEDA
Tidsramme: At baseline (T0) and at 6 hours after supine repositioning (T3)
Right Ventricular End-Diastolic Area to Left Ventricular End-Diastolic Area Ratio
At baseline (T0) and at 6 hours after supine repositioning (T3)
RVFAC
Tidsramme: Baseline and 6h post-supine repositioning (T3)
Right Ventricular Fractional Area Change(%)
Baseline and 6h post-supine repositioning (T3)
TAPSE
Tidsramme: Baseline and 6h post-supine repositioning (T3)
Tricuspid Annular Plane Systolic Excursion (mm)
Baseline and 6h post-supine repositioning (T3)
TRVmax
Tidsramme: Baseline and 6h post-supine repositioning (T3)
Maximal Tricuspid Regurgitation Velocity (m/s)
Baseline and 6h post-supine repositioning (T3)
LVEF
Tidsramme: At baseline (T0) and at 6 hours after supine repositioning (T3)
Left Ventricular Ejection Fraction(%)
At baseline (T0) and at 6 hours after supine repositioning (T3)
SV
Tidsramme: Baseline and 6h post-supine repositioning (T3)
Stroke Volume(ml)
Baseline and 6h post-supine repositioning (T3)
CO
Tidsramme: Baseline and 6h post-supine repositioning (T3)
Cardiac Output (L/min)
Baseline and 6h post-supine repositioning (T3)
28-Day Mortality
Tidsramme: At 28 days after enrollment
All-cause mortality within 28 days after enrollment.
At 28 days after enrollment
Ventilator-Free Days at 28 Days
Tidsramme: At 28 days after enrollment
Number of days alive and free from invasive mechanical ventilation during the first 28 days after enrollment.
At 28 days after enrollment
ICU Length of Stay
Tidsramme: From enrollment through ICU discharge, assessed up to 28 days
Total duration of ICU stay (in days) from enrollment to ICU discharge or death.
From enrollment through ICU discharge, assessed up to 28 days
Incidence of ECMO Use
Tidsramme: During the ICU stay, assessed up to 28 days
Proportion of patients requiring veno-venous extracorporeal membrane oxygenation (VV-ECMO) during the ICU stay.
During the ICU stay, assessed up to 28 days
Incidence of Tracheostomy
Tidsramme: During the ICU stay, assessed up to 28 days.
Proportion of patients undergoing tracheostomy during the ICU stay.
During the ICU stay, assessed up to 28 days.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Min Xie, Tongji Hospital

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

31. august 2026

Primær færdiggørelse (Anslået)

20. maj 2027

Studieafslutning (Anslået)

30. juni 2027

Datoer for studieregistrering

Først indsendt

20. august 2026

Først indsendt, der opfyldte QC-kriterier

26. august 2026

Først opslået (Faktiske)

28. august 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

28. august 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

26. august 2026

Sidst verificeret

1. august 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • TJ-IRB202605019

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner